Caris Life Sciences Announces a Strategic Collaboration with Ontada® to Advance Oncology Research and the Adoption of Precision Medicine
Txylo.com/10298175

IRVING, Texas, Jan. 16, 2025 ~ In a groundbreaking move, Caris Life Sciences® (Caris) has announced a strategic collaboration with Ontada®, a leading business in oncology real-world evidence and clinical education. This partnership aims to advance molecular research and cancer care, as well as improve the healthcare delivery system through the use of precision medicine.

According to Caris President David Spetzler, MS, PhD, MBA, this collaboration is rooted in a commitment to rigorous science and cancer care. The partnership will focus on three key pillars: the development and delivery of multimodal data solutions, innovative research strategies, and data-driven practices to provide actionable cancer care intelligence.

The goal of this collaboration is to revolutionize cancer research by seamlessly integrating key entities such as research, biopharma, and patients. By doing so, they hope to drive innovation and ultimately improve patient outcomes.

Ontada President Christine Davis also expressed excitement about the collaboration, stating that by bringing together two extensive clinical and genomic data sets from community oncology settings, they have created a unique resource for life sciences companies. This resource will empower them to address complex questions and potentially lead to groundbreaking research that can improve cancer care.

More on Txylo.com

• $750 Million Ketamine Drug Market Withing Reach via New Commissioner's National Priority Vouchers with Anticipated Approval by Year-End for NRx
• NUFABRX awarded Therapeutic Compression agreement with Premier, Inc
• Luxurious Estate in Keenes Pointe Hits the Market at $2.9 Million
• Simplilearn Partners with Michigan Engineering Professional Education to Launch Generative AI Applications for Leaders Program
• CredHub and ManageAmerica Partner to Empower Residents Through Seamless Rent Reporting Integration

The collaboration will leverage Caris' molecular-rich database generated from over 6.5 million tests producing over 13 quadrillion datapoints. Additionally, Ontada's industry-leading real-world oncology data representing over 2.4 million cancer patient records across more than 80 tumor types will be available for research. This data is largely derived from community settings where an estimated 85% of cancer patients are treated according to the National Cancer Institute.

By bringing together expertise in cancer care, diagnostics, and drug development, this collaboration goes beyond just providing a combined data solution. It also aims to advance oncology treatment through joint research projects.

Chairman of the Caris Precision Oncology Alliance™ James Hamrick MD MPH believes that this partnership will bridge the gap between research and real-world application. This will create a streamlined pathway from research and development to clinical practice, ultimately benefiting patients with faster access to more informed treatment decisions, personalized therapies, clinical trials, and improved outcomes.

In conclusion, this collaboration between Caris and Ontada marks a transformative approach to cancer care. It fosters innovation, efficiency, and patient-centered outcomes in oncology. With the rapid evolution of oncology, this partnership is poised to deliver insights more quickly and conduct more robust research that will advance precision care.

---

Show All News | Report Violation